Repligen gets orphan drug status for pancreas MRI (magnetic resonance imaging) agent
This article was originally published in Clinica
Executive Summary
Repligen has been granted orphan drug designation from the US FDA to use its synthetic human secretin product as a contrast agent during magnetic resonance imaging (MRI) of the pancreas.